Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Stopped early · Phase 1/Phase 2
Conditions studied: Non Hodgkin Lymphoma
In brief
The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.
Key facts
- Study ID
- NCT02953509
- Run by
- Gilead Sciences
- People needed
- 178
- Starts
- 2016-11-21
- Expected to finish
- 2024-03-25
- Last updated by the study team
- 2025-05-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama At Birmingham (Uab) — Birmingham, Alabama, United States
- City of Hope National Medical Center — Duarte, California, United States
- Stanford Cancer Center — Stanford, California, United States
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- National Institutes of Health Clinical Center/ National Cancer Institute — Bethesda, Maryland, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- University of Minnesota Medical Center, Fairview — Minneapolis, Minnesota, United States
- Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- The Sarah Cannon Research Institute — Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Princess Alexandra Hospital — Brisbane, Queensland, Australia
- St. Vincent's Hospital Melbourne — Melbourne, Victoria, Australia
- Linear Clinical Research Ltd — Nedlands, Western Australia, Australia
- The Churchill Hospital — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.